Modulatory role for CCK-B antagonists in Parkinson's disease.

Abstract

We examined the ability of selective CCK-A and CCK-B receptor antagonists to induce or modulate the locomotor stimulant effects of dopamine agonists in MPTP-treated squirrel monkeys. Administration of 1-100 micrograms/kg i.p. of either the selective CCK-A receptor antagonist devazepide (MK-329) or the CCK-B receptor antagonist L-365,260 alone failed to stimulate a locomotor response in parkinsonian monkeys. In contrast, treatment with L-365,260 caused a 50-60% potentiation of the locomotor stimulatory effects of L-DOPA or (+)-PHNO. No such modulatory effects were observed following pretreatment with devazepide. We suggest that CCK-B receptor antagonists may be useful adjuncts to existing dopamine replacement therapy for improved management of Parkinson's disease.

• Authors: S Boyce, N M Rupniak, S Tye, M J Steventon, S D Iversen
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) Vol. 13 Issue 4 Pg. 339-47 (Aug 1990) ISSN: 0362-5664 [Print] United States
• PMID: 1976438 (Publication Type: Journal Article)

Chemical References

• Benzodiazepinones
• Dopamine Agents
• Oxazines
• Phenylurea Compounds
• Receptors, Cholecystokinin
• naxagolide
• L 365260
• Levodopa
• Cholecystokinin
• Devazepide
• Carbidopa

Topics

• Animals
• Benzodiazepinones (antagonists & inhibitors, pharmacology)
• Carbidopa (pharmacology)
• Cholecystokinin (antagonists & inhibitors, pharmacology)
• Devazepide
• Dopamine Agents (pharmacology)
• Levodopa (pharmacology)
• MPTP Poisoning
• Male
• Motor Activity (drug effects)
• Oxazines (pharmacology)
• Parkinson Disease, Secondary (chemically induced, physiopathology)
• Phenylurea Compounds
• Receptors, Cholecystokinin (antagonists & inhibitors, physiology)
• Saimiri